Myeloproliferative Disorders  >>  Pegasys (pegylated interferon α -2a)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
MPD-RC 112, NCT01259856: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Completed
3
168
US, Europe
PEGASYS, Pegylated Interferon Alfa-2a, Hydroxyurea, Hydroxycarbamide, Aspirin, acetylsalicylic acid
Ronald Hoffman, Myeloproliferative Disorders-Research Consortium, National Cancer Institute (NCI), Roche Pharma AG
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
06/17
06/17

Download Options